EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review



Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review



Clinical and Experimental Rheumatology 26(6): 1125-1133



While intravenous (IV) bisphosphonates are well established in managing metastatic bone disease and hypercalcemia of malignancy, oral bisphosphonates are the primary treatment for postmenopausal osteoporosis. The availability of a well-tolerated, effective, IV bisphosphonate regimen for postmenopausal osteoporosis would increase physicians' options, allowing treatment of patients who cannot tolerate oral therapy, for whom oral bisphosphonates should be avoided or patients who are unable to comply with the oral dosing recommendations. Ibandronate is a potent, nitrogen-containing bisphosphonate, with proven efficacy and good tolerability when administered intermittently either orally or intravenously. Preclinical experience in animal models with IV ibandronate indicated that it had good renal tolerability. These data are supported by clinical pharmacology studies. Prolonged follow-up of patients receiving intermittent IV 15-30 second injections of 0.5-3 mg IV ibandronate has demonstrated no clinical evidence of renal toxicity in patients with postmenopausal osteoporosis. What is seen in controlled studies is not always the case in uncontrolled studies, however, no reports of renal failure have been received in post-marketing surveillance of >500,000 patients receiving IV ibandronate infusions in various indications including metastatic breast and prostate cancer. The good renal tolerability of IV ibandronate in patients with osteoporosis with glomerular filtration rates >30 mL/minute and without renal co-morbid conditions is reassuring.

(PDF emailed within 1 workday: $29.90)

Accession: 055490608

Download citation: RISBibTeXText

PMID: 19210886



Related references

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Journal of Rheumatology 35(3): 488-497, 2008

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone 46(3): 660-665, 2010

Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Current Pharmaceutical Design 11(28): 3711-3728, 2005

Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease – the DIVINE study. Bone 49(6): 0-1322, 2011

Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study. Bone 49(6): 1317-1322, 2012

Tri-monthly intravenous injections of ibandronate for treatment of postmenopausal osteoporosis. Journal of Bone & Mineral Research 16(Suppl 1): S406, September, 2001

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. American Journal of Medicine 103(4): 298-307, 1997

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: A review of three Phase II studies. Clinical Therapeutics 25(1): 19-34, January, 2003

The MOTION study: Tolerability of monthly ibandronate and weekly alendronate in women with postmenopausal osteoporosis. 2007

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis and Rheumatism 54(6): 1838-1846, 2006

Quarterly intravenous ibandronate for postmenopausal osteoporosis. Women's Health 4(3): 219-228, 2009

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Annals of the Rheumatic Diseases 65(5): 654-661, 2005

Bone histomorphometric evaluation of daily and intermittent oral ibandronate in postmenopausal osteoporosis. Calcified Tissue International 72(4): 402, April, 2003